Rodrigues, Ana
Chauhan, Jyoti
Sagkriotis, Alexandros
Aasaithambi, Sathyaraj
Montrone, Michele
Article History
Received: 22 December 2021
Accepted: 4 April 2022
First Online: 30 April 2022
Declarations
:
: All data utilized and presented in the present SML study were obtained from publicly accessible sources without accessing password-protected information. All personal identifiers were removed from the downloaded data to anonymize the information. This study received internal pharmacovigilance approval [registry ID GSMR 2631 (V1)] by Novartis AE and safety reporting team. All methods were performed in accordance with the relevant guidelines and regulations involving the secondary use of social media research [CitationRef removed].
: Not applicable.
: <i>A. Rodrigues:</i> Personal non-financial interests for training with AstraZeneca, and personal non-financial interests in advisory boards for MSD, BMS, AstraZeneca, Boehringer Ingelheim, Roche; <i>M. Montrone:</i> Speaker’s bureau fees from AstraZeneca, Boehringer Ingelheim, Roche, MSD, BMS; <i>A. Sagkriotis</i> is an employee of Novartis and a shareholder<i>; S. Aasaithambi</i> and <i>J. Chauhan</i> are employees of Novartis